Close

Lilly To Provide Detailed Update Of Pipeline And R&D Strategy At Upcoming Investment Community Meeting

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

APAC Drug Industry 2026: From Manufacturing Hub to Innovation Powerhouse

For years, APAC was mainly known for producing medicines...

Study Identifies Tiered Manufacturing in Global Pharmaceutical Markets

A new research project from the Johns Hopkins Bloomberg...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.
- Advertisement -

Eli Lilly and Company announced it will host a meeting for the investment community, including institutional investors, sell-side analysts, ratings agency representatives, and financial and business media.

World pharma today/Industry reports/- The meeting will take place Tuesday, May 24, 2016, from 10:00 a.m. (EDT) until approximately 3:00 p.m., inNew York City.

The investment community meeting will focus on Lilly’s research and development opportunities in diabetes, immunology, oncology and pain. It follows a similar meeting in December 2015 to review the company’s broad Alzheimer’s disease pipeline. The presentations will include discussion of new indications and line extensions for a number of established products as well as late-stage and select earlier-stage new molecular entities. There will be Q&A opportunities throughout the meeting.

A live webcast of the Lilly investment community meeting, along with presentation slides, will be available through a link on the investor section of Lilly’s website at https://investor.lilly.com/events.cfm. An audio replay will also be available for approximately one month.

Because of limited space, advance registration is required. Media interested in attending in person should contactMolly McCully at (317) 478-5423. Investors interested in attending should contact Edward Villacorta at (317) 433-1805.

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

APAC Drug Industry 2026: From Manufacturing Hub to Innovation Powerhouse

For years, APAC was mainly known for producing medicines...

Study Identifies Tiered Manufacturing in Global Pharmaceutical Markets

A new research project from the Johns Hopkins Bloomberg...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »